JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Bristol-Myers Squibb Co.

Geschlossen

BrancheGesundheitswesen

45.64 7.14

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

42.63

Max

45.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.1B

1.3B

Verkäufe

1.1B

12B

KGV

Branchendurchschnitt

17.638

37.003

EPS

1.46

Dividendenrendite

5.61

Gewinnspanne

10.702

Angestellte

34,100

EBITDA

-1.2B

3.3B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+20.31% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

5.61%

2.25%

Nächste Dividendenausschüttung

3. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-6.2B

89B

Vorheriger Eröffnungskurs

38.5

Vorheriger Schlusskurs

45.64

Nachrichtenstimmung

By Acuity

38%

62%

121 / 373 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Bristol-Myers Squibb Co. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. Okt. 2025, 11:14 UTC

Ergebnisse

Bristol Myers Squibb 3Q Profit Soars, Raises Revenue Guidance

10. Okt. 2025, 12:32 UTC

Akquisitionen, Fusionen, Übernahmen

Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion

31. Juli 2025, 11:14 UTC

Ergebnisse

Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q

30. Okt. 2025, 16:52 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera -- WSJ

30. Okt. 2025, 16:52 UTC

Akquisitionen, Fusionen, Übernahmen

Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ

30. Okt. 2025, 11:32 UTC

Ergebnisse

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. -- Barrons.com

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis, Which Was More Than Offset by Expected Continued Generic Impact Across Remainder of Legacy Portfolio >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb: Revised 2025 Adj EPS Guidance Inclusive of 80c Loss Per Shr Net Impact Related to Acquired IPRD Charges and Licensing Income >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 3Q Adjusted Gross Margin 72.9% >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 3Q U.S. Revenue Rose 1% to $8.33B >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb Raises 2025 Rev Guidance to $47.5B-$48B Vs Prior Outlook $46.5B-$47.5B >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb: Raised 2025 Rev Guidance Primarily Reflects Continued Strong Performance of Growth Portfolio >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 3Q International Revenue Rose 6% to $3.89B >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb: 3Q Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Reblozyl, Camzyos and Breyanzi >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 3Q Legacy Portfolio Rev Fell 12% to $5.37B >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb Adjusts 2025 View To Adj EPS $6.40-Adj EPS $6.60 Vs Prior Outlook $6.35-$6.65 >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 3Q Gross Margin 71.9% >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 3Q Growth Portfolio Revenue Rose 18% to $6.86B >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb: Latest 3Q Includes Net Impact of Loss of 20c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 3Q Adj EPS $1.63 >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 3Q Rev $12.22B >BMY

30. Okt. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 3Q EPS $1.08 >BMY

10. Okt. 2025, 16:19 UTC

Akquisitionen, Fusionen, Übernahmen

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10. Okt. 2025, 11:02 UTC

Akquisitionen, Fusionen, Übernahmen

Bristol-Myers Squibb to Pay $1.5B in Cash at Closing to Acquire Orbital >BMY

10. Okt. 2025, 11:01 UTC

Akquisitionen, Fusionen, Übernahmen

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio With Acquisition of Orbital Therapeutics

4. Aug. 2025, 11:59 UTC

Ergebnisse

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

31. Juli 2025, 11:54 UTC

Ergebnisse

Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update

31. Juli 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B >BMY

31. Juli 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb Cuts 2025 View To Adj EPS $6.35-Adj EPS $6.65 Vs Prior View $6.70-$7.00 >BMY

31. Juli 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 2Q Adjusted Gross Margin 72.6% >BMY

Peer-Vergleich

Kursveränderung

Bristol-Myers Squibb Co. Prognose

Kursziel

By TipRanks

20.31% Vorteil

12-Monats-Prognose

Durchschnitt 51.25 USD  20.31%

Hoch 65 USD

Tief 34 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bristol-Myers Squibb Co. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

20 ratings

5

Buy

14

Halten

1

Sell

Technischer Score

By Trading Central

N/A / 50.57Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

121 / 373 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
help-icon Live chat